Effect of daprodustat on renal anemia in patients with chronic kidney disease

Effect of daprodustat on renal anemia in patients with chronic kidney disease - Effect of daprodustat on renal anemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041546

Enrollment

Registered

2020-09-01

Start date

2020-09-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

Daprodustat tablets are orally administered once daily. The dose of daprodustat tablet is appropriately increased or decreased depending on the blood hemoglobin concentration.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic kidney disease patients with renal anemia

Exclusion criteria

Exclusion criteria: Patients complicated with serious diseases such as malignancy, heart failure (NYHA III degrees or more), and liver cirrhosis

Design outcomes

Primary

Measure	Time frame
Hemoglobin concentration, serum iron, transferrin saturation, serum ferritin, hepcidin	—

Countries

Japan

Contacts

Public ContactMichio Kuwahara

Saitama Tsukinomori Clinic Division of Nephrology

kuwahara@k-naika-cl.jp0487921811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026